Novartis shareholders may receive a hard copy of either of these documents, each of which contains our complete audited financial statements, free of charge, upon request. Annual Report 2023 (PDF 3.7 MB) | Form 20-F 2023 (PDF 3.5 MB) Order the publications Other...
For an explanation of non-IFRS measures and reconciliation tables, see the Annual Report 2023 "—Non-IFRS measures as defined by Novartis.” In the first quarter of 2023Lucentiswas reclassified from other promoted brands to established brands andGilenyawas reclassified from neuroscience to established...
Novartis is included in several rankings that evaluate our performance in various categories, including in DEI. Diversity, Equity & Inclusion Related Themes People & Culture Code of Ethics Environmental, Society and Governance Annual Report Our Strategy...
人狂犬病疫苗(Novartis ): 一种免疫刺激剂药物,由Novartis Vaccines & Diagnostics, Inc. (Novartis Vaccines & Diagnostics, Inc.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: 免疫刺激剂,治疗领域: 感染,其他疾病,在研适应症: 狂犬病,在研机构: Chi
This statistic was assembled from several editions of Novartis' annual report. * With the 2015 Annual Report, values back to 2011 were restated, as a result of a series of transactions during 2015. ** During this year, eye care division Alcon was spun off and became an own company. Thus...
Sep 19, 2022 Analyzing Google’s pharma strategy: How the tech giant is expanding its presence in drug development Jun 2, 2022 Here are the 9 most impressive biopharma founding teams funded in the past 2 years — and what they signal about the future of the industry ...
Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy 2011; 66: 317-330. Kimball A, Prens E, Bechara F, et al. Efficacy and safety of ...
Analysts at Jefferies have previously said that iptacopan could hit $3.6 billion in peak annual sales if it gets approved for all its target indications, which along with PNH, include atypical haemolytic uraemic syndrome (aHUS) and rare kidney diseases C3 glomerulopathy (C3G) and idiopathic membran...
Factors that may affect GSK’s operations include, but are not limited to, those described under Item 3.D “Principal risks and uncertainties” in GSK’s Annual Report on Form 20-F for 2017. Subject to the requirements of the Financial Conduct Authority (“FCA...
Berger, et al., “New Directions in Research: Report from the 10th Internation Conference of AIDS,” Canadian Medical Association Journal 152(12);1991-1995 (1995). Berman, et al., “Human Immunodeficiency Virus Type 1 Challenge of Chimpanzees Immunized with Recombinant Envelope Glycoprotein gp120...